

<b><u>RSV Immunization Recommendations for Infants and Pregnant Individuals</u></b>		
<b><u>RSV Product</u></b>	<b><u>Age Recommendation</u></b>	<b><u>Timing for Administration</u></b>
<b><u>Nirsevimab (Beyfortus)</u></b> <ul style="list-style-type: none"> <li>• <b>50 mg</b> – weighing less than 5 kg (11 lbs.)</li> </ul>	All infants <8 months born during or entering their <i>first</i> RSV season	<ul style="list-style-type: none"> <li>• October 1, 2025 – March 31, 2026</li> <li>• Infants born during the months of April – September should receive a single dose in October</li> </ul>
<b><u>Nirsevimab (Beyfortus)</u></b> <ul style="list-style-type: none"> <li>• <b>100 mg</b> – weighing greater than 5 kg (11 lbs.)</li> </ul>	All infants <8 months born during or entering their <i>first</i> RSV season	<ul style="list-style-type: none"> <li>• October 1, 2025 – March 31, 2026</li> <li>• Infants born during the months of April – September should receive a single dose in October</li> </ul>
<b><u>Nirsevimab (Beyfortus)</u></b> <ul style="list-style-type: none"> <li>• <b>200 mg</b> (administered as two - 100 mg injections)</li> </ul>	Some children age 8 months – 19 months who are at increased risk for severe RSV entering their <i>second</i> season	<ul style="list-style-type: none"> <li>• October 1, 2025 – March 31, 2026</li> </ul>
<b><u>Clesrovimab (Enflonsia)</u></b> <ul style="list-style-type: none"> <li>• <b>105 mg</b> – no weight restrictions</li> </ul>	All infants <8 months born during or entering their <i>first</i> RSV season only.	<ul style="list-style-type: none"> <li>• October 1, 2025 – March 31, 2026</li> <li>• Infants born during the months of April 2025 – September 2025 should receive a single dose in October</li> </ul>
<b><u>Palivizumab (Synagis)</u></b> <ul style="list-style-type: none"> <li>• <b>50 mg or 100 mg</b> monthly dosing</li> </ul>	No longer recommended (administer an RSV monoclonal antibody product instead)	<ul style="list-style-type: none"> <li>• No longer recommended</li> </ul>
<b><u>Maternal Immunization for RSV</u></b>		
<b><u>Abrysvo (Pfizer)</u></b> <b>0.5 mL</b> – single, one-time dose	For pregnant women at 32–36 weeks gestational age	<ul style="list-style-type: none"> <li>• September 1, 2025 – January 31, 2026</li> <li>• If Abrysvo is not administered at 32-36 weeks gestation, an RSV monoclonal antibody product should be administered directly to the newborn if born during the months of February 1, 2026 – March 31, 2026</li> </ul>